Analysis of herpes zoster cases in multiple sclerosis patients treated with disease-modifying drugs: insights from the EudraVigilance database | Synapse
March 15, 2026
Analysis of herpes zoster cases in multiple sclerosis patients treated with disease-modifying drugs: insights from the EudraVigilance database
Key Points
To evaluate the risk of herpes zoster (HZ) in multiple sclerosis (MS) patients undergoing treatment with disease-modifying drugs (DMTs).
Analyzed data from the EudraVigilance database
Focused on cases of herpes zoster among multiple sclerosis patients
Assessed the need for vaccination against herpes zoster
Identified a risk of herpes zoster in MS patients treated with DMTs
Suggested that vaccination could reduce adverse events associated with treatment
Highlighted the importance of evaluating HZ risk during MS treatment
Abstract
While treating MS patient with DMTs the risk of adverse HZ should be evaluated. Vaccination against HZ should be recommended for patients to benefit the most from the available treatment.